Masimo (MASI) stock is in focus after the company received FDA 510(k) clearance for its pediatric Patient State Index sedation score, extending the SedLine brain monitoring suite to children four years and older.

The FDA clearance comes as Masimo’s share price sits at US$179.95, with a year to date share price return of 41.25% and a 1 year total shareholder return of 7.09%. This suggests momentum has picked up recently after weaker multi year total returns.

If this kind of medical technology progress interests you, it could be a good moment to broaden your watchlist with other healthcare related AI opportunities identified in the 41 healthcare AI stocks

Masimo looks like a robust medical technology business, and the recent FDA win has clearly caught the market’s attention. After such a strong share price move, does the current valuation still leave much appeal for new money?

Most Popular Narrative: Fairly Valued

Masimo's most followed valuation narrative pegs fair value at $180, almost exactly in line with the recent close at $179.95. Attention therefore shifts to the assumptions that underpin that figure.

The expansion of dedicated specialty sales teams and realignment of the commercial structure is expected to drive increased market share in high-growth categories like capnography, brain monitoring, and hemodynamics, where current share is below 20%, which should accelerate top-line revenue growth and elevate long-term earnings.

This raises the question of what kind of revenue path and profit profile support that fair value for Masimo. The narrative leans on rising margins and a richer earnings multiple. The detailed playbook sits inside the full set of assumptions that power this calculation.

Result: Fair Value of $180 (ABOUT RIGHT)

However, Masimo still faces pressure from potential tariff changes and the ongoing shift toward lease accounting, which could unsettle margins and reported revenue growth assumptions.

Another View on Masimo Using Market Ratios

While the Masimo fair value narrative sits around $180, the current P/E ratio of 43.5x is higher than both the peer average of 38.1x and a fair ratio estimate of 26.1x. That gap points to valuation risk if the market eventually moves closer to the lower fair ratio. How comfortable are you with paying that kind of premium?

Next Steps

The mix of enthusiasm and caution around Masimo is clear. It makes sense to move quickly, review the data, and decide where you stand using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Masimo?

If Masimo has your attention, do not stop there. Use the Simply Wall Street Screener to uncover fresh opportunities that could strengthen and diversify your portfolio.

• Spot potential value opportunities early by reviewing companies highlighted in the 53 high quality undervalued stocks.
• Prioritise resilience by checking out companies identified in the 82 resilient stocks with low risk scores.
• Target consistent income by scanning opportunities in the 7 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.